Log In Sign up
The largest database of trusted experimental protocols
> Living Beings > Bacterium > Probiotics

Probiotics

Probiotics are live microorganisms, typically bacteria or yeasts, that are believed to provide health benefits when consumed.
They are often referred to as 'good' or 'friendly' bacteria because they can help maintain a healthy balance of microorganisms in the gut.
Probiotics may assist in digestion, boost the immune system, and promote overall wellbeing.
They are commonly found in fermented foods like yogurt, kefir, and sauerkraut, as well as in dietary supplements.
Reseach on the potential health effects of probiotics is an active area of study, with promising results but some inconsistencies.
More high-quality studies are needed to fully understand the optimal strains, dosages, and applications of probiotucs.

Most cited protocols related to «Probiotics»

1
Evaluating Search Filters for Animal Studies
Our newly developed search filter for detecting all studies in PubMed in which laboratory animals are used or described was compared with the easily available and most obvious method (‘regular method’), the PubMed Limit: Animals. The number of records obtained with the two different methods was compared. In addition, both the search filter and the limit option were validated by actually performing two PubMed topic searches. The first topic search aimed at finding all available literature in PubMed about probiotic use in experimental pancreatitis (Supplement 1a, available online at http:la.rsmjournals.com/cgi/content/full/la.2010.009117/DC1 ).
The second topic search tried to identify all studies about food restriction in laboratory animals (Supplement 1b, available online at http:la.rsmjournals.com/cgi/content/full/la.2010.009117/DC1 ).
The number of records found with our search filter as a proportion of the number of records retrieved by the Limit: Animals was calculated. We will refer to this proportion as the sensitivity* of the search filter.
Hooijmans C.R., Tillema A., Leenaars M, & Ritskes-Hoitinga M. (2010). Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in PubMed. Laboratory Animals, 44(3), 170-175.
Full text: Click here
Publication 2010
Animals Animals, Laboratory Dietary Supplements Feeds, Animal Food Hypersensitivity Pancreatitis Probiotics
2
Pediatric Crohn's Disease Microbiome Study

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Antibiotics Archaea Bacteria Base Sequence Biological Assay Child Crohn Disease DNA Library Endoscopy Feces Freezing Gene Expression Genes Genome Homo sapiens Inflammation Metagenome Microbiome Mucositis Ostomy Parenteral Nutrition Patients Pharmaceutical Preparations Physicians Probiotics
3
Consensus Development of Core Outcomes for Preterm Birth Prevention
A protocol with explicitly defined objectives, formal consensus development methods, criteria for participant identification and selection, and statistical methods was developed. The study was prospectively registered with the Core Outcome Measures in Effectiveness Trials (COMET) initiative (registration number 603 available online at www.comet-initiative.org/studies/details/603). The ethics board of the Academic Medical Center, Amsterdam, The Netherlands, advised that ethical approval was not required (reference number E2-172) because this project should be considered as service evaluation and development.
The target of the core outcome set was to capture important outcomes for individual studies, systematic reviews, and guidelines for preterm birth prevention in asymptomatic woman. For our purposes, preterm birth was defined as neonates born alive before 37 weeks of gestation.5 (link) An asymptomatic woman was defined as one without symptoms of preterm labor (e.g increased uterine contractions, menstrual cramps of backache, color change of vaginal discharge, prelabor rupture of membranes). Preventive treatment of preterm birth was defined as one started before any symptoms of preterm labor were present. This preventive strategy could be pharmacologic (e.g. progesterone, marine oils, probiotics) or non-pharmacologic (e.g. cerclage, pessary, lifestyle interventions and alternative therapies).
A Project Steering Committee was established to give guidance to the different phases of this project consisting of two obstetricians (Irene de Graaf, Khalid S. Khan), two neonatologists (Timo de Haan, Stephen Kempley), two midwives (Felipe Castro, Birgit van der Goes), two patient representatives (Aoife Ahern, Mandy Daly) and three methodologists with experience in formal consensus and/or core outcome set methods (James Duffy, Brent Opmeer, and Paula Williamson).
A systematic literature review was undertaken searching the Cochrane Pregnancy and Childbirth Group's (PCG) Trials Register.1 The Pregnancy and Childbirth Group register is maintained by monthly searches of the Cochrane Central Register of Controlled Trials and weekly searches of EMBASE and MEDLINE and hand-searches of 30 journal and conference proceedings (from January 1997 to January 2011). The register was searched utilizing the register’s codes for preterm birth. Two reviewers (S.M. and Z.A.) independently screened titles and abstracts. They critically reviewed the full text of selected studies and extracted reported outcomes. Any discrepancies were resolved by discussion. In addition, all delegates (n=168) of the First European Spontaneous Preterm Birth Congress (Svendborg, Denmark, May 24–25, 2014), mainly representing obstetricians and researchers, but also midwives, neonatologists and members of industry, were requested via e-mail to recommend potential outcomes.
Patient representatives and parents were invited through social media (Twitter and patient forums on Facebook) to participate in an online questionnaire to share their opinions regarding outcomes relevant to preterm birth. Members of patient organisations including the European foundation for the Care of Newborn Infants, their partner organizations, and parental forums of neonatal baby units were e-mailed by their own organization including an invitation for the online questionnaire through an electronic newsletter. Patients also contributed their opinions through in-person semistructured interviews conducted by one of the authors (J.v.t.H.).
The Project Steering Committee identified outcomes that were duplicated as a result of varied terminologies used by different stakeholders and for grouping closely related outcomes into overarching domains. This outcome inventory of 29 outcomes was entered into a Delphi process (Figure 1).
We used a two-round electronic Delphi survey design, a well-established method to elicit consensus based on an iterative process with anonymous consultation and with controlled feedback and quantified analysis of the responses.6 A priori we agreed the important methodological features for our Delphi process: [1] composition of the group; [2] anonymity; [3] how to assess the importance of outcomes; [4] method of feedback of results to participants; [5] how consensus would be reached; [6] how to assess possible attrition bias.
The setting for the Delphi survey was multinational involving stakeholders from middle- and high-income countries. A formal written invitation was e-mailed to all members of the Cochrane Pregnancy and Childbirth group (n=30), the Core Outcomes in Women’s Health initiative (n=77), the European Preterm Birth Congress (n=168), and the Global Obstetrics Network (n=237). Most members of these organizations are researchers (methodologists), obstetricians (mainly specialized in maternal fetal medicine) or neonatologists. The European foundation for the Care of Newborn Infants approached their members themselves, including their partner organizations in Australia, Belgium, Bulgaria, Canada, Chile, Croatia, Cyprus, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lithuania, Mexico, the Netherlands, Norway, Poland, Portugal, Spain, Turkey, United Kingdom, and the United States. All midwifes from ‘Barts Health Nursing and Midwifery’ (n=132) and some midwifes of the School of Nursing and Midwifery (Galway, Ireland) and the Dutch Consortium for Healthcare Evaluation in Obstetrics and Gynaecology were approached. With this approach we aimed to targeted midwifes who were active in research (50%) and midwifes who were not active in research (50%). In total 337 obstetricians, 152 midwives, 174 researchers, 75 neonatologists, and an unknown number of parents (through the previously mentioned patient organizations) were invited.
We used LimeSurvey for the Delphi survey. The survey was piloted first by eight people representing every stakeholder group. No changes were needed after the pilot. The official survey had a closing date of 5 weeks after the date of invitation for every Delphi round. An e-mail reminder was sent to participants on days 7, 14, 21, and 28. Nonresponders in the first round were not invited to participate in the subsequent round.
Participants were asked to rate the importance of each outcome on a 9-point Likert scale anchored between 1 (‘limited importance’) and 9 (‘critical importance’). The scale is recommended by the Grading of Recommendations Assessment, Development and Evaluation working group: 1–3: limited importance; 4–6: important but not critical; 7–9: critical.7 (link) Participants were invited to recommend additional potential outcomes for consideration at the end of the survey using free-text responses.
The individual, stakeholder group and total results from the first round were relayed back to participants by e-mail; the individual responses directly after filling in the first round questionnaire, the stakeholder group, and total group responses were fed back anonymously 1 day prior to the invitation to the second round of the Delphi survey. Furthermore, participants of the second survey were able to see the mean value of the total group responses from the first Delphi round while completing the survey. Participants were asked to score all the individual outcomes again using the same 9-point Likert scale. No outcomes were excluded in this round to ensure a holistic approach to scoring in round 2.
The Delphi survey responses were analyzed using SPSS version 21.0. For each outcome the median and interquartile range were calculated. Frequency tables of all scores were generated, as well as boxplots for visualization (that were used to relay back the whole and stakeholder group responses). We defined consensus a priori. Core outcomes required at least 70% of participants in each stakeholder group scoring the outcome as ‘critical’ and less than 15% of participants in each stakeholder group scoring the outcome as ‘limited importance’.8 (link) Outcomes which should not be included in a core outcome set required at least 70% of participants in each stakeholder group scoring the outcome as ‘limited importance’ and less than 15% of participants in each stakeholder group scoring the outcome as ‘critical’. If outcomes did not meet either criteria they were classified as outcomes with no consensus. Attrition bias (e.g. a selective group did not respond to the second round of the survey or a selective group participated in the consultation meeting) was assessed by 1) comparing the distribution of median first round scores across the outcomes for those not participating in the second round with those who did; and 2) comparing the distribution of median round 2 scores across the outcomes for those participating in the consultation meeting compared with those who did not.
The final phase of the study was a face-to-face consultation meeting with participants of the Delphi exercise representing all stakeholder groups (Washington, DC, November 9, 2014). This meeting was organized within a meeting for a prospective individual participant data analysis project for studies on the use of pessary in the prevention of preterm birth in asymptomatic women. Eleven participants of this prospective individual patient data project did also took part in the Delphi survey earlier. They mainly represented the stakeholder groups of obstetricians and methodologists. Representatives from the other stakeholder groups (parents, midwives and neonatologists), who were living close to the location of the consultation meeting, were invited for this consultation meeting as well. In total 23 obstetricians, 10 researchers, two neonatologists, two patient representatives, and one midwife were invited to attend this meeting. Information material on the purpose of the consultation meeting and the Delphi round 2 results were sent to participants before the meeting. A plenary presentation on the Delphi survey outcomes was complemented by small group sessions (mixed groups) where participants expressed their views on the candidate outcomes. Only outcomes that did not reach full consensus in the Delphi exercise were presented to the attendees of the meeting with an anonymous voting using electronic touchpads. Consensus in the consultation meeting required a majority of 70% of participants from each stakeholder group approving an individual outcome as ‘critical’ according to the 1–9 Likert scale. With the permission of the participants the consultation meeting was recorded.
van ‘t Hooft J., Duffy J.M., Daly M., Williamson P.R., Meher S., Thom E., Saade G.R., Alfirevic Z., J. Mol B.W, & Khan K.S. (2016). A Core Outcome Set for Evaluation of Interventions to Prevent Preterm Birth. Obstetrics and gynecology, 127(1), 49-58.
Publication 2016
Alternative Therapies Back Pain Childbirth Comet Assay Dysmenorrhea Europeans Face Fetal Membranes, Premature Rupture Genetic Code Infant Infant, Newborn Marines Midwife Neonatologists Obstetrician Oils Parent Patient Representatives Patients Pessaries Pregnancy Premature Birth Premature Obstetric Labor Probiotics Progesterone Tooth Attrition Uterine Contraction Woman
4
Premenopausal Women Bacterial Vaginosis Study
The Health Sciences Research Ethics Board at the University of Western Ontario granted ethical approval for the study under approval number REB16183E. Participants gave their signed informed consent before the start of the study. Premenopausal women between the ages of 18-40 years were recruited at the Victoria Family Medical Center in London, Canada. Participants were excluded from the study if they reached menopause, were menstruating, had a urogenital infection other than BV in the past 6 months, were pregnant, had a history of gonorrhoea, chlamydia, estrogen-dependent neoplasia, abnormal renal function or pyelonephritis, were taking prednisone, immunosuppresives or antimicrobial medication, had undiagnosed abnormal vaginal bleeding, had engaged in oral or vaginal intercourse or consumed probiotic ements or foods in the 48 hours prior to the clinical visit.
Fernandes A.D., Macklaim J.M., Linn T.G., Reid G, & Gloor G.B. (2013). ANOVA-Like Differential Expression (ALDEx) Analysis for Mixed Population RNA-Seq. PLoS ONE, 8(7), e67019.
Full text: Click here
Publication 2013
Chlamydia Coitus Estrogens Food Gonorrhea Infection Kidney Menopause Microbicides Neoplasms Pharmaceutical Preparations Prednisone Probiotics Pyelonephritis System, Genitourinary Woman
5
Probiotics Effect on Gut Microbiome
Eighteen healthy volunteers (age: 22 ± 3.16 yrs, 6 male, 12 female) were recruited through Azabu University, Kanagawa, Japan (Supplementary Table S1). All subjects were informed of the purpose of this study. This study was approved by the ethical committee of Azabu University, and written consent was obtained from all subjects. No subjects were treated with antibiotics during faecal sample collection. The subjects were divided into six groups (three subjects per group), and each group consumed six different commercially available probiotics supplied from Yakult Honsha Co., Ltd, Kagome Co., Ltd, Morinaga Milk Industry Co., Ltd, Takanashi Milk Products Co., Ltd, Meiji Co., Ltd, and Danone Japan Co., Ltd, respectively (Supplementary Table S1). The number of each bacterial strain contained in the probiotic products was estimated as the genome equivalent by qPCR of 16S ribosomal RNA genes using 27Fmod-338R, followed by pyrosequencing of the 16S amplicons (see below). The genome equivalent per gram or millilitre and the total genome equivalent of each bacterial strain in one probiotic product are summarized in Supplementary Table S1. Three subjects in each group consumed the same probiotics daily for 8 weeks according to the schedule of sampling and probiotic intervention (Supplementary Fig. S1). Faecal samples from 4 weeks before (S00) and 8 weeks during probiotic intervention (S01–S04), and 8 weeks after cessation of probiotic intervention (S05–S08), were collected every 2 weeks from each subject. In total, we collected 158 faecal samples from the 18 subjects because we could not collect 1 sample each from 4 of the subjects.
Kim S.W., Suda W., Kim S., Oshima K., Fukuda S., Ohno H., Morita H, & Hattori M. (2013). Robustness of Gut Microbiota of Healthy Adults in Response to Probiotic Intervention Revealed by High-Throughput Pyrosequencing. DNA Research: An International Journal for Rapid Publication of Reports on Genes and Genomes, 20(3), 241-253.
Publication 2013
Antibiotics, Antitubercular Bacteria Feces Females Genome Genome, Bacterial Healthy Volunteers Males Milk Probiotics Ribosomal RNA Genes Specimen Collection Strains

Most recents protocols related to «Probiotics»

1
Probiotic Molecules Inhibit HAV Infection
Not available on PMC !

Example 11

The effects of probiotic molecule-containing CFSM on cells that are infected with HAV was studied. Control cells are shown in FIG. 19A. CFSM from Lactobacillus lactis La-5 (FIG. 19B), L. reuteri (FIG. 19C), and Lactococcus lactis (FIG. 19D) were applied to a monolayer of cells infected with HAV and a decrease in the infection of HAV was observed. The arrows in these figures point at the infected cells and the rest of the cells comprise the uninfected monolayer.

US11857581B2. Antiviral methods and compositions comprising probiotic bacterial molecules (2024-01-02). MicroSintesis Inc. [CA]. Inventors: Mansel Griffiths [CA].
Full text: Click here
Patent 2024
Infection Lactobacillus delbrueckii subsp. lactis Lactobacillus reuteri Lactococcus lactis Probiotics
2
Antiviral Properties of Probiotic Compounds
Not available on PMC !

Example 10

CFSM was initially applied to virus-free cell cultures to determine the concentration of CFSM that could be used on FRhK cells without itself causing any detrimental effects on the cells. In FIGS. 17A and 17B, it can be seen that 2% CFSM is a desirable amount to use and this amount was used for subsequent experiments.

Next, viral particles in infected RAW 264.7 cells and media in the presence of probiotic CFSM were quantified. Mouse macrophage RAW 264.7 cells were infected with MNV-1 at 1×106 cells with 3.5×106 PFU. After RNA extraction from cells and media (supernatant), quantification of MNV-1 particles was done by a 2-step real-time PCR. The analysis showed a statistical difference (t-test, p<0.05) between the amounts of viral particles present in the media (FIG. 18, panel B) compared to untreated infected cells. For the number of viral particles inside the cells, only Lactococcus lactis and Lactobacillus reuteri (FIG. 18, panel A), showed a statistical difference compared to infected cells, however, Lactobacillus acidophilus La-5 showed a trend towards statistical significance. These results show that the propagation of MNV-1 might be negatively affected by the presence of bioactive compounds produced by probiotic strains.

US11857581B2. Antiviral methods and compositions comprising probiotic bacterial molecules (2024-01-02). MicroSintesis Inc. [CA]. Inventors: Mansel Griffiths [CA].
Full text: Click here
Patent 2024
Cells Lactobacillus acidophilus Lactobacillus reuteri Lactococcus lactis Macrophage Mus Norovirus Infection Probiotics RAW 264.7 Cells Real-Time Polymerase Chain Reaction Strains Virion Virus Vision
3
Evaluating Lactobacillus Probiotic Resistance
Not available on PMC !

Example 5

The Lactobacillus ingested through the oral cavity passes through the stomach with the lower acidity and the intestines with high digestive enzymes and are exposed to low pH of gastric acid, pepsin, intestinal bile salts and digestive enzymes. Therefore, in order to utilize microorganisms as probiotics, gastric juice resistance is essential to survive in low pH and enzymes, and bile juice resistance is essential to survive in extreme intestinal environment. In accordance with the present disclosure, experiments were conducted to identify resistance to artificial gastric juice and bile juice of the above two strains with superior inhibitory effects against Gardnerella vaginalis and Candida albicans. The pH of the gastric juice in the body is maintained at about 3.0, and the food passes through the stomach for about 3 hours. In general, when maintaining viable cell count for 3 hours or more at pH 3, the cells has the high resistance to acidity. In order to identify the intestinal viability of Lactobacillus, survival experiments for artificial gastric juice and artificial bile juice were conducted with reference to Maragkoudakis' method. MG4272 and MG4288 strains were streaked on MRS plate medium and incubated at 37° C. for 24 hours, and the resulting colonies were inoculated in MRS liquid medium and incubated (37° C., 24 hours). Then, 2% passage was incubated for 24 hours in fresh MRS medium. The culture medium was then centrifuged (4,000×g, 4° C., 5 minutes) and washed twice with phosphate-buffer saline (PBS, pH 7.4). The washed cells were adjusted to OD600 1.0 (108 to 109 CFU/mL) and used for resistance experiments to the artificial gastric juice and artificial bile solution, respectively. As a control, 900 μL of pH 7 PBS was added to 100 μL of diluted Lactobacillus and the mixture was shaken and the number of viable cells was measured immediately. In order to identify the resistance to gastric juice, pepsin (Sigma-Aldrich, Saint Louise, USA) was dissolved in 3 g/L of pH 3 to pH 4 PBS to prepare an artificial gastric juice. 100 μL of lactobacillus diluent was added to 900 μL of artificial gastric juice, shaken, and cultured at 37° C. In 3 hours, the viable cell count was measured. To identify resistance to the artificial bile juice, pancreatin (Sigma-Aldrich, Saint Louise, USA) was dissolved in 1 g/L at pH 7 to pH 8 to prepare artificial bile juice. 100 μL of lactobacillus diluent was added to 900 μL of artificial bile juice, shaken and incubated at 37° C. In 4 hours, the viable cell count was measured. The measured results are shown in Table 1 in terms of log CFU/ml.

TABLE 1
Artificial gastric juiceArtificial bile solution
Selectedtest grouptest group
strainsControlpH 3pH 4pH 7pH 8
MG42728.53 ± 0.018.47 ± 0.018.52 ± 0.018.52 ± 0.028.49 ± 0.02
MG42888.46 ± 0.068.40 ± 0.048.44 ± 0.028.41 ± 0.018.41 ± 0.02

As shown in Table 1 both strains of MG4272 and MG4288 were identified to maintain the viable cell count of 108 CFU/mL or more after 3 hours at pH 3, thereby identifying excellent acid resistance. In the artificial bile resistance test, both strains of MG4272 and MG4288 were identified to maintain the viable cell count of 108 CFU/mL or more, thereby identifying excellent bile resistance.

US11857580B2. Lactobacillus having antimicrobial effect on Gardnerella vaginalis and Candida albicans (2024-01-02). MEDIOGEN CO., LTD. [KR], None [KR]. Inventors: Nam-Soo Paek [KR], Chang Ho Kang [KR].
Full text: Click here
Patent 2024
Acids Bile Buffers Candida albicans Cells Culture Media Digestion Enzymes Food Gardnerella vaginalis Gastric Acid Heartburn Human Body Intestines Juices, Gastric Lactobacillus Oral Cavity Pancreatin Pepsin A Phosphates Probiotics Psychological Inhibition Saline Solution Salts, Bile Stomach Strains
4
Periodontitis Adjunct Therapy Protocol
Not available on PMC !

Example 7

    • Initial full mouth one-stage disinfection by rinsing for 2 minutes with a 0.12% chlorhexidine solution.
    • 6 months oral administration of 10 mg of bioavailable silicic acid in the form of choline-stabilized orthosilicic acid (ch-OSA®), wherein silicic acid is stabilized with choline chloride, suitably in the form of two dosage units each containing 5 mg bioavailable silicic acid;
    • Daily administration of two probiotic lozenges, each containing 2 viable strains of Lactobacillus reuteri (1 108 CFU), for instance DSM17938 and ATCC PTA5289, during 6 months.

It is herein preferable, that the administration of the bioavailable silicic acid and the administration of the probiotic lozenges start simultaneously. Alternatively, the administration of the bioavailable silicic acid may precede the administration of the probiotic lozenges during a preparatory period of for instance 3 days up to 14 days, for instance 1 week.

US11878031B2. Silicic acids for use in the treatment of periodontitis (2024-01-23). Bio Minerals N.V. [BE]. Inventors: Mario Remi Yvonne Calomme [BE], Kathleen Jozef Ingrid Suzanne Van Hoof [BE].
Full text: Click here
Patent 2024
Acids Administration, Oral Chlorhexidine Choline Choline Chloride Disinfection Dosage Forms Lactobacillus reuteri Periodontitis Probiotics Silicic acid Strains
5
Probiotic Supplement Formulation and Preparation
Not available on PMC !

Example 1

NAME OF COMPONENTmg/sachet
Probiotic Material:
Lactobacillus helveticus150 billion CFU/g73.333
Rosell 52
Bifidobacterium longum 50 billion CFU/g20.000
R175
Lactobacillus plantarum150 billion CFU/g20.000
Rosell 1012
Carrier material:
Magnesium oxide41.446
Magnesium gluconate341.297
Potassium citrate138.290
Zinc gluconate111.111
Glutathione20.000
Lactoferrin11.364
Copper citrate2.834
Inulin500.000
Fructose1291.125
Additional (optional) excipients
Sucralose4.000
Acesulfame K12.000
Flavouring150.000
Aerosil 20040.000
Colouring: E1242.200
Colouring: E1021.000
Anhydrous citric acid220.000

The formulation described above is prepared as follows: Lactobacillus Plantarum, Lactobacillus helveticus, Bifidobacterium longum, are mixed with inulin and blended at 32 rpm for approximately 10 min. Thereafter, fructose, magnesium gluconate, zinc gluconate, citric acid, flavor, potassium citrate, magnesium oxide, silicon dioxide, glutathione, potassium acesulfame, lactoferrine, and sucralose are added to the mixture and blended at 32 rpm for another 10 min.

US11878040B2. Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin (2024-01-23). GlaxoSmithKline Consumer Healthcare S.R.L. [RO]. Inventors: Valeria Longoni [IT], Marisa Penci [IT].
Full text: Click here
Patent 2024
acesulfame potassium Aerosil Bifidobacterium longum Citric Acid Citric Acid, Anhydrous Copper Excipients Flavor Enhancers Fructose gluconate Glutathione Inulin Lactobacillus Lactobacillus helveticus Lactobacillus plantarum Lactoferrin Magnesium magnesium gluconate Minerals Oxide, Magnesium Oxides Potassium Citrate Prebiotics Probiotics Salts Silicon Dioxide sucralose zinc gluconate

Top products related to «Probiotics»

1
Mrs broth by Thermo Fisher Scientific
Sourced in United Kingdom, Italy, United States, Australia, Spain, Canada, Sweden, Belgium, Norway, Germany
MRS broth is a microbiological medium used for the selective isolation and cultivation of lactobacilli. It provides the necessary nutrients and growth factors for the optimal growth of lactobacilli species. The composition of the broth includes various peptones, yeast extract, glucose, and specific salts.
2
Mrs broth by Merck Group
Sourced in Germany, United States, United Kingdom, Singapore, Japan, Spain
MRS broth is a culture medium used for the isolation and cultivation of lactic acid bacteria, particularly Lactobacillus species. It provides the necessary nutrients and growth factors required by these microorganisms. The formulation of MRS broth is based on the de Man, Rogosa, and Sharpe (MRS) medium.
3
Mrs broth by BD
Sourced in United States, Japan
MRS broth is a microbiological culture medium used for the isolation and cultivation of lactic acid bacteria. It provides the necessary nutrients and growth factors for the proliferation of these bacteria in a laboratory setting.
4
Mrs broth by HiMedia
Sourced in India, United States
MRS broth is a culture medium used for the isolation and enumeration of lactic acid bacteria. It provides nutrients required for the growth of Lactobacillus species and other lactic acid bacteria.
5
Mrs agar by Merck Group
Sourced in Germany, United States, Italy, United Kingdom, Hungary, Poland
MRS agar is a laboratory culture medium used for the selective isolation and enumeration of lactic acid bacteria. It is designed to support the growth of organisms such as Lactobacillus, Pediococcus, and Leuconostoc species. MRS agar provides the necessary nutrients and growth factors required by these microorganisms.
6
Mrs agar by Thermo Fisher Scientific
Sourced in United Kingdom, United States, Germany, Italy, China, Spain
MRS agar is a growth medium used for the isolation and cultivation of lactic acid bacteria, particularly Lactobacillus species. It provides essential nutrients and growth factors required by these microorganisms. The formulation is based on de Man, Rogosa, and Sharpe's (MRS) original recipe.
7
Glycerol by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, France, India, Spain, Canada, Switzerland, China, Brazil, Australia, Japan, Ireland, Indonesia, Hungary, Malaysia, Sao Tome and Principe, Sweden, Singapore, Macao, Belgium, Mexico, Romania, Netherlands, Poland, Israel, Portugal, Colombia, New Zealand, Pakistan, Denmark
Glycerol is a colorless, odorless, and viscous liquid used in various laboratory applications. It is a basic chemical compound with the molecular formula C₃H₈O₃. Glycerol is commonly used as a solvent, humectant, and stabilizer in many laboratory procedures.
8
Prism 8 by GraphPad
Sourced in United States, Austria, Canada, Belgium, United Kingdom, Germany, China, Japan, Poland, Israel, Switzerland, New Zealand, Australia, Spain, Sweden
Prism 8 is a data analysis and graphing software developed by GraphPad. It is designed for researchers to visualize, analyze, and present scientific data.
9
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
10
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.

More about "Probiotics"

Probiotics are beneficial live microorganisms, often referred to as 'good' or 'friendly' bacteria, that can help maintain a healthy balance of gut microbiota.
These microbes, typically bacteria or yeasts, are believed to provide a variety of health benefits when consumed.
Probiotics may assist in digestion, boost the immune system, and promote overall wellbeing.
Probiotics are commonly found in fermented foods like yogurt, kefir, and sauerkraut, as well as in dietary supplements.
The MRS (de Man, Rogosa, and Sharpe) broth and MRS agar are commonly used media for the cultivation and isolation of probiotic strains, such as Lactobacillus and Bifidobacterium species.
Resarch on the potential health effects of probiotics is an active area of study, with promising results but some inconsistencies.
More high-quality studies, leveraging tools like Prism 8 and SAS version 9.4, are needed to fully understand the optimal strains, dosages, and applications of probiotics.
The growing interest in probiotics has led to the development of AI-driven platforms, such as PubCompare.ai, which can help optimize probiotic research by locating the best protocols from literature, pre-prints, and patents.
These platforms utilize AI-driven comparisons to enhance reproducibility and accuracy, empowering researchers to identify the most effective probiotics products and protocols.
Whether you're a healthcare professional, a researcher, or a consumer interested in the benefits of probiotics, staying informed about the latest developments in this dynamic field is crucial.
By understanding the science behind probiotics, the available tools and resources, and the potential health implications, you can make more informed decisions and contribute to the advancement of this exciting area of study.